📊 This is a company profile preview from Tablestat.com Request a Free Trial Now

Company profile: Infant Bacterial Therapeutics

1.1 - Company Overview

Infant Bacterial Therapeutics Logo

Infant Bacterial Therapeutics

Headquarter: Sweden
Founded: 20XX🔒
Employees: 100-500🔒

Company description

  • Provider of clinical-stage pharmaceutical drug development focused on influencing the infant microbiome to prevent or treat rare diseases in infants. Developing IBP-9414 to prevent NEC in premature infants; IBP-9414 contains the active substance Lactobacillus reuteri, a human bacterial strain.

Products and services

🔒

Key contacts

🔒
🔒

Financial details

🔒

1.2 - Competitors and similar companies to Infant Bacterial Therapeutics

Novira Therapeutics Logo

Novira Therapeutics

HQ: United States Website
  • Description: Provider of antiviral drug discovery focused on first-in-class oral therapeutics targeting the viral capsid to treat chronic HBV and HIV infections, addressing diseases with high unmet need.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Novira Therapeutics company profile →
Destiny Pharma Logo

Destiny Pharma

HQ: United Kingdom Website
  • Description: Provider of novel antimicrobial products in clinical development, including XF-73 Nasal for prevention of post-surgical Staphylococcal infections (preparing for Phase 3), NTCD-M3 to prevent recurring C. difficile gut infections (preparing for Phase 3), XF-73 Dermal for skin infections, an XF platform with a rapid mechanism that reduces resistance, and biotherapeutic programs for infection prevention.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Destiny Pharma company profile →
Anadys Pharmaceuticals Logo

Anadys Pharmaceuticals

HQ: United States Website
  • Description: Provider of biopharmaceutical therapeutics for chronic hepatitis C, developing ANA598, a direct-acting antiviral (DAA), and resuming clinical development of ANA773.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Anadys Pharmaceuticals company profile →
ProStrakan Logo

ProStrakan

HQ: United Kingdom Website
  • Description: Provider of specialty pharmaceutical development and commercialisation of prescription medicines for unmet therapeutic needs in major markets; headquartered in Scotland with more than 300 employees and commercial operations.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full ProStrakan company profile →
Bluejay Therapeutics Logo

Bluejay Therapeutics

HQ: United States Website
  • Description: Provider of biopharmaceutical drug candidates for infectious diseases, including BJT-778, a fully human IgG1 monoclonal antibody designed to neutralize and facilitate clearance of HDV virions, contributing to a potential functional cure for CHB/CHD, and BJT-628, an oral liver-targeted HBV transcript inhibitor reducing HBsAg. Offers the Bluejay L-TAP platform for liver-targeted oral delivery and runs Phase 1/2a trials in chronic hepatitis B.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Bluejay Therapeutics company profile →
🔒

2.M&A buyers

2.1 Potential strategic acquirers in the sector

🔒
🔒
🔒
🔒 View all strategic buyers with complete profiles
Start Free Trial →

2.2 - Strategic buyer groups for Infant Bacterial Therapeutics

🔒

Buyer group 1: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 2: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 3: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to Infant Bacterial Therapeutics

2.2 - Growth funds investing in similar companies to Infant Bacterial Therapeutics

🔒 View all growth equity funds with complete profiles
Start Free Trial →

4 - Top valuation comps for Infant Bacterial Therapeutics

4.2 - Public trading comparable groups for Infant Bacterial Therapeutics

🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →

4.3 - M&A Transactions similar to Infant Bacterial Therapeutics

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA
🔒 View all M&A transactions with complete deal terms
Request Free Trial Now →

Frequently Asked Questions

About Infant Bacterial Therapeutics

What does Infant Bacterial Therapeutics do?

Infant Bacterial Therapeutics is a provider of clinical-stage pharmaceutical drug development focused on influencing the infant microbiome to prevent or treat rare diseases in infants. Developing IBP-9414 to prevent NEC in premature infants; IBP-9414 contains the active substance Lactobacillus reuteri, a human bacterial strain.

Who are Infant Bacterial Therapeutics's competitors?

Infant Bacterial Therapeutics's competitors and similar companies include Novira Therapeutics, Destiny Pharma, Anadys Pharmaceuticals, ProStrakan, and Bluejay Therapeutics.

Where is Infant Bacterial Therapeutics headquartered?

Infant Bacterial Therapeutics is headquartered in Sweden.

How many employees does Infant Bacterial Therapeutics have?

Infant Bacterial Therapeutics has 1,000 employees 🔒.

When was Infant Bacterial Therapeutics founded?

Infant Bacterial Therapeutics was founded in 2010 🔒.

What sector and industry vertical is Infant Bacterial Therapeutics in?

Infant Bacterial Therapeutics is in the Enterprise Software 🔒 sector and industry

M&A Buyers & Acquirers for Infant Bacterial Therapeutics

Who are the top strategic acquirers in Infant Bacterial Therapeutics's sector and industry

Top strategic M&A buyers and acquirers in Infant Bacterial Therapeutics's sector include ████████, ██████████, ██████, ████████, and ██████████ 🔒.

Which M&A buyer groups are most relevant for Infant Bacterial Therapeutics?

Top strategic M&A buyers groups and sectors for Infant Bacterial Therapeutics include █████████████████ , ████████████████, █████████████, ████████████, and ████████████████ 🔒.

Financial Investors investing in Infant Bacterial Therapeutics's sector and industry vertical

Which are the top PE firms investing in Infant Bacterial Therapeutics's sector and industry vertical?

Top PE firms investing in Infant Bacterial Therapeutics's sector and industry vertical include ████████, ██████████, ████████, and ██████████ 🔒.

Who are the top buyout funds acquiring in Infant Bacterial Therapeutics's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in Infant Bacterial Therapeutics's sector and industry vertical include █████████, ██████████, ████████████, and ████████████ 🔒.

Who are the top growth equity funds investing in companies in Infant Bacterial Therapeutics's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to Infant Bacterial Therapeutics include █████████, ██████████, ████████████, and ████████████ 🔒.

Valuation benchmarks of companies in Infant Bacterial Therapeutics's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for Infant Bacterial Therapeutics?

The key public trading comparables and valuation benchmarks for Infant Bacterial Therapeutics include █████████, ██████████, ████████████, and ████████████ 🔒.

Which are the key trading comparable groups for Infant Bacterial Therapeutics for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for Infant Bacterial Therapeutics with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in Infant Bacterial Therapeutics's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for Infant Bacterial Therapeutics with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in Infant Bacterial Therapeutics's' sector and industry vertical?

Access recent funding rounds and capital raises in Infant Bacterial Therapeutics's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for Infant Bacterial Therapeutics